Casein

Identification

Name
Casein
Accession Number
DB10516
Type
Biotech
Groups
Approved
Biologic Classification
Allergenics
Allergen Extract
Description

Casein allergenic extract is used in allergenic testing.

Synonyms
  • Bovine casein
  • Calcium caseinate
  • Casein allergenic extract
  • Casein, cow milk
  • Casein, milk
  • Milk casein
  • Milk protein
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CaseinInjection, solution.1 mg/mLPercutaneousAlk Abello, Inc.1965-01-01Not applicableUs
CaseinInjection, solution.05 g/mLIntradermal; SubcutaneousNelco Laboratories, Inc.1972-08-29Not applicableUs
CaseinInjection, solution.1 g/mLIntradermal; SubcutaneousNelco Laboratories, Inc.1972-08-29Not applicableUs
CaseinInjection, solution.05 g/mLIntradermal; SubcutaneousNelco Laboratories, Inc.1972-08-29Not applicableUs
CaseinInjection, solution.1 g/mLIntradermal; SubcutaneousNelco Laboratories, Inc.1972-08-29Not applicableUs
Food - Dairy Products, Casein, Cow MilkInjection, solution.1 g/mLPercutaneous; SubcutaneousJubilant Hollisterstier Llc1941-04-19Not applicableUs
Food - Dairy Products, Casein, Cow MilkInjection, solution.1 g/mLPercutaneousJubilant Hollisterstier Llc1941-04-19Not applicableUs
Categories
UNII
48268V50D5
CAS number
9000-71-9

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCasein may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCasein may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Casein.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Casein.Approved
AlfacalcidolThe risk or severity of adverse effects can be increased when Casein is combined with Alfacalcidol.Approved, Nutraceutical
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Casein.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Casein.Approved
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Casein.Approved
AranidipineThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Casein.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Casein.Approved, Investigational
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Casein.Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Casein.Approved
BencyclaneThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Casein.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Casein.Approved, Investigational
BenzthiazideBenzthiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Casein.Approved, Withdrawn
BioallethrinThe therapeutic efficacy of Bioallethrin can be decreased when used in combination with Casein.Approved, Experimental
CalcidiolThe risk or severity of adverse effects can be increased when Casein is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Casein is combined with Calcipotriol.Approved
CalcitriolThe risk or severity of adverse effects can be increased when Casein is combined with Calcitriol.Approved, Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Casein is combined with Calcium Acetate.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Casein.Investigational
CaroverineThe therapeutic efficacy of Caroverine can be decreased when used in combination with Casein.Experimental
CeftriaxoneThe risk or severity of adverse effects can be increased when Casein is combined with Ceftriaxone.Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Casein.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Casein is combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Casein.Approved, Investigational
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Casein.Approved, Investigational
CinoxacinCasein can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinCasein can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Casein.Approved, Investigational
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Casein.Approved, Investigational, Vet Approved
CyclandelateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Casein.Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Casein which could result in a higher serum level.Experimental
CymarinCasein may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Casein.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Casein.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Casein.Approved
DeslanosideCasein may increase the arrhythmogenic activities of Deslanoside.Approved
DigitoxinCasein may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinCasein may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Casein may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Casein is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Casein.Approved, Investigational
Dipotassium phosphateCasein can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Casein.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Casein.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Casein.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Casein is combined with Doxercalciferol.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Casein.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Casein.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Casein.Approved
EnoxacinCasein can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Casein.Approved, Investigational
EpitizideEpitizide may decrease the excretion rate of Casein which could result in a higher serum level.Experimental
ErgocalciferolThe risk or severity of adverse effects can be increased when Casein is combined with Ergocalciferol.Approved, Nutraceutical
EstramustineCasein can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Casein.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Casein.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Casein.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Casein.Withdrawn
Fish oilThe therapeutic efficacy of Fish oil can be decreased when used in combination with Casein.Approved, Nutraceutical
FleroxacinCasein can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlumequineCasein can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Casein.Approved
FluspirileneThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Casein.Approved, Investigational
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Casein.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Casein.Investigational
GarenoxacinCasein can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCasein can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCasein can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GitoformateCasein may increase the arrhythmogenic activities of Gitoformate.Experimental
GrepafloxacinCasein can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved, Investigational
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Casein.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Casein.Approved, Investigational
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Casein.Approved, Investigational
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Casein.Approved, Investigational
Lanatoside CCasein may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Casein.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Casein.Approved, Investigational
LevofloxacinCasein can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Casein.Approved
LidoflazineThe therapeutic efficacy of Lidoflazine can be decreased when used in combination with Casein.Experimental
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Casein.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Casein.Approved
Lipoic AcidCasein can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
LomefloxacinCasein can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoperamideThe therapeutic efficacy of Loperamide can be decreased when used in combination with Casein.Approved
Magnesium sulfateThe therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Casein.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Casein.Approved, Investigational
MentholThe therapeutic efficacy of Menthol can be decreased when used in combination with Casein.Approved
MethsuximideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Casein.Approved
MethyclothiazideMethyclothiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
MetildigoxinCasein may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetolazoneMetolazone may decrease the excretion rate of Casein which could result in a higher serum level.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Casein.Investigational, Withdrawn
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Casein.Approved, Investigational
MoxifloxacinCasein can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Casein.Investigational
Nalidixic AcidCasein can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NemonoxacinCasein can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Casein.Approved, Investigational
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Casein.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Casein.Experimental
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Casein.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Casein.Approved, Investigational
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Casein.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Casein.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Casein.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Casein.Approved, Investigational
NorfloxacinCasein can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Casein.Approved
OfloxacinCasein can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCasein may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Casein.Experimental, Investigational
OuabainCasein may increase the arrhythmogenic activities of Ouabain.Approved
Oxolinic acidCasein can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Casein.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Casein.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol.Approved, Investigational
PazufloxacinCasein can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCasein can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PeruvosideCasein may increase the arrhythmogenic activities of Peruvoside.Experimental
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Casein.Approved
Pipemidic acidCasein can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidCasein can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PolythiazidePolythiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Casein.Withdrawn
ProscillaridinCasein may increase the arrhythmogenic activities of Proscillaridin.Experimental
PrulifloxacinCasein can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Casein which could result in a higher serum level.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Casein.Approved, Investigational
RosoxacinCasein can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinCasein can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SeletracetamThe therapeutic efficacy of Seletracetam can be decreased when used in combination with Casein.Investigational
SitafloxacinCasein can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateCasein can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateCasein can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinCasein can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Casein.Approved, Withdrawn
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Casein.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Casein.Approved
TemafloxacinCasein can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe therapeutic efficacy of Terodiline can be decreased when used in combination with Casein.Experimental
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Casein.Approved, Vet Approved
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Casein.Investigational
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Casein.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Casein.Approved, Investigational, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Casein.Approved, Investigational
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Casein.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Casein.Approved, Investigational
TrimebutineThe therapeutic efficacy of Trimebutine can be decreased when used in combination with Casein.Approved
TrimethadioneThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Casein.Approved
TrovafloxacinCasein can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Casein.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Casein.Investigational
WIN 55212-2The therapeutic efficacy of WIN 55212-2 can be decreased when used in combination with Casein.Experimental
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Casein.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Casein.Approved
ZonisamideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Casein.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910679
Wikipedia
Casein

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntradermal; Subcutaneous.05 g/mL
Injection, solutionIntradermal; Subcutaneous.1 g/mL
Injection, solutionPercutaneous.1 mg/mL
Injection, solutionPercutaneous.1 g/mL
Injection, solutionPercutaneous; Subcutaneous.1 g/mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on June 02, 2018 08:21